Iteos Therapeutics Stock Retained Earnings
| ITOS Stock | USD 6.88 0.01 0.15% |
Iteos Therapeutics fundamentals help investors to digest information that contributes to Iteos Therapeutics' financial success or failures. It also enables traders to predict the movement of Iteos Stock. The fundamental analysis module provides a way to measure Iteos Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Iteos Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Retained Earnings | -9.8 M | -9.3 M | |
| Retained Earnings Total Equity | 272.9 M | 286.5 M |
Iteos | Retained Earnings |
Iteos Therapeutics Company Retained Earnings Analysis
Iteos Therapeutics' Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
More About Retained Earnings | All Equity Analysis
Retained Earnings | = | Beginning RE + Income | - | Dividends |
Current Iteos Therapeutics Retained Earnings | (9.78 M) |
Most of Iteos Therapeutics' fundamental indicators, such as Retained Earnings, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Iteos Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Iteos Retained Earnings Driver Correlations
Understanding the fundamental principles of building solid financial models for Iteos Therapeutics is extremely important. It helps to project a fair market value of Iteos Stock properly, considering its historical fundamentals such as Retained Earnings. Since Iteos Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Iteos Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Iteos Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.
| Competition |
Based on the latest financial disclosure, Iteos Therapeutics has a Retained Earnings of (9.78 Million). This is 101.05% lower than that of the Biotechnology sector and 110.09% lower than that of the Health Care industry. The retained earnings for all United States stocks is 100.1% higher than that of the company.
Iteos Retained Earnings Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Iteos Therapeutics' direct or indirect competition against its Retained Earnings to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Iteos Therapeutics could also be used in its relative valuation, which is a method of valuing Iteos Therapeutics by comparing valuation metrics of similar companies.Iteos Therapeutics is currently under evaluation in retained earnings category among its peers.
Iteos Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Iteos Therapeutics from analyzing Iteos Therapeutics' financial statements. These drivers represent accounts that assess Iteos Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Iteos Therapeutics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 1.2B | 1.6B | 694.3M | 310.8M | 279.8M | 265.8M | |
| Enterprise Value | 848.9M | 794.8M | 414.2M | 173.8M | 199.9M | 189.9M |
Iteos Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Iteos Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Iteos Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Iteos Fundamentals
| Return On Equity | -0.23 | ||||
| Return On Asset | -0.14 | ||||
| Operating Margin | (4.48) % | ||||
| Current Valuation | (226.77 M) | ||||
| Shares Outstanding | 38.19 M | ||||
| Shares Owned By Insiders | 1.10 % | ||||
| Shares Owned By Institutions | 91.18 % | ||||
| Number Of Shares Shorted | 1.58 M | ||||
| Price To Earning | 50.50 X | ||||
| Price To Book | 0.45 X | ||||
| Price To Sales | 7.51 X | ||||
| Revenue | 35 M | ||||
| Gross Profit | 35 M | ||||
| EBITDA | (153.09 M) | ||||
| Net Income | (134.41 M) | ||||
| Cash And Equivalents | 791.86 M | ||||
| Cash Per Share | 22.26 X | ||||
| Total Debt | 5.1 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 6.42 X | ||||
| Book Value Per Share | 16.14 X | ||||
| Cash Flow From Operations | (98.18 M) | ||||
| Short Ratio | 5.23 X | ||||
| Earnings Per Share | (3.32) X | ||||
| Target Price | 25.0 | ||||
| Number Of Employees | 173 | ||||
| Beta | 1.38 | ||||
| Market Capitalization | 262.97 M | ||||
| Total Asset | 686.98 M | ||||
| Retained Earnings | (9.78 M) | ||||
| Working Capital | 469.18 M | ||||
| Net Asset | 686.98 M |
About Iteos Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Iteos Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Iteos Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Iteos Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Iteos Stock Analysis
When running Iteos Therapeutics' price analysis, check to measure Iteos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iteos Therapeutics is operating at the current time. Most of Iteos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Iteos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iteos Therapeutics' price. Additionally, you may evaluate how the addition of Iteos Therapeutics to your portfolios can decrease your overall portfolio volatility.